### Alert

**ORAL ADMINISTRATION ONLY**

The first dose of rotavirus vaccine should be given to infants between 6 and 14 weeks chronological age (prior to turning 15 weeks chronological age) and the second dose by 24 weeks of age (prior to turning 25 weeks of age). The interval between dose 1 and 2 should not be less than 4 weeks.

From July 2017, only Rotarix will be made available under National Immunisation Program in Australia.

Regular look up for any online updates by the Australian Immunisation Register is recommended.

### Indication

Primary immunisation of infants against rotavirus gastroenteritis.

### Action

Live attenuated human rotavirus vaccine that induces protective immunity against the G1P(8) strain and some other non-G1 prevalent strains of rotavirus.

### Drug Type

Vaccine.

### Trade Name

Rotarix

### Presentation

1.5 mL oral suspension in an oral applicator with plunger stopper.

### Maximum Daily Dose

See “Total Cumulative Dose”

### Total Cumulative Dose

Limited data on the safety of administering higher than the recommended dose.

### Dosage / Interval

1.5 mL orally.

**Primary schedule:** 2-dose course administered with 2- and 4-month immunisations i.e., dose 1 can be administered at 6 to 14 weeks of age and dose 2 can be administered at 14 to 24 weeks of age.

**NOTE:** Dosage interval between first and second doses must be greater than 4 weeks.

<table>
<thead>
<tr>
<th>Schedule</th>
<th>Age limit for first dose</th>
<th>Age limit for second dose</th>
<th>Minimum interval between doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 oral doses (1.5 mL/dose)</td>
<td>6–14 weeks</td>
<td>14–24 weeks</td>
<td>4 weeks</td>
</tr>
</tbody>
</table>

**NOTE:** If most of the oral rotavirus vaccine has been regurgitated or vomited within minutes of administration, a single repeat dose can be administered during the same immunisation encounter. If an infant regurgitates or vomits only a small part of a vaccine dose, it is not necessary to repeat the dose.

**Catch-up schedule:** If an infant has NOT had a dose of any rotavirus vaccine AND is ≥ 15 weeks then that infant is NOT ELIGIBLE to commence any rotavirus vaccination dose.¹

**Preterm infants:** Vaccine is administered at a chronologic age (without correction for prematurity) similar to term infants, if the infant is clinically stable.¹

**Hospitalised infants:** If standard infection control precautions are maintained and the infant is medically stable, vaccination should not be delayed, particularly if the delay would result in an infant being beyond the upper age limit for vaccination.¹

**Systemic corticosteroid therapy:** Rotavirus vaccine is not contraindicated in neonates on inhaled or systemic corticosteroids if they are otherwise medically stable. (personal communication with Australian Immunisation Registry experts Kristine Macartney and Jim Buttery).¹

**Other live vaccines:** Rotavirus vaccine can be given at any time before or after the routine infant immunisations and at any time before or after BCG vaccine. The recommendation for administering live vaccines either at the same time or after an interval of four weeks only applies to injectable live viral vaccines and, therefore, not to BCG or to the oral rotavirus vaccines.²
### Route

Oral or via gastric tube

### Administration

**Oral:** Administer entire applicator or dosing tube content on inside of cheek with child in reclining position.

**Gastric tube:** For infants who can’t take the vaccine orally, it can be administered via a gastric tube; flush with air to clear the tube.

Can be given with or without feeds.

Record details of vaccination in patient’s Personal Health Record ('Blue Book') and medication chart.

Other vaccines can be given at the same time (refer to Drug interactions section).

### Monitoring

Anaphylaxis following a previous dose of rotavirus vaccine.

Anaphylaxis following any vaccine component.

Previous history of intussusception or a congenital abnormality that may predispose to intussusception. Fatal intussusception after the second dose has been reported in infants with a history of intussusception after the first dose.

Severe Immunocompromise.

Severe Combined Immunodeficiency (SCID).

Do not administer to (i) infants older than 24 weeks of age as safety has not been demonstrated, particularly in relation to risk of intussusception, (ii) infants with malformation of the gastrointestinal tract that could predispose them to intussusception, (iii) hereditary fructose intolerance, glucose/galactose malabsorption or sucrase-isomaltase insufficiency.

If infant is > 14 weeks and inadvertently receives 1st dose of rotavirus vaccine, reassure parents and discuss minimally increased risk of intussusception. Provide information on symptoms/signs of intussusception.

If infant is < 25 weeks (upper limit for dose 2 of rotavirus vaccine), and minimum interval of 4 weeks between vaccine doses can be achieved, give a second dose of rotavirus vaccine

### Contraindications

Use with caution in infants with underlying conditions predisposing to severe rotavirus gastroenteritis (including metabolic disorders or chronic gastrointestinal disease e.g., Hirschsprung’s disease, malabsorption syndromes or short gut syndrome).

Severe acute gastroenteritis (e.g. necrotising enterocolitis)

Significant acute illness or temperature greater than 38°C (postpone vaccine until neonatologist approves).

Use with caution in immunosuppressed infants (the theoretical risk for vaccine virus-associated disease is considered likely to be less than their risk from being exposed to disease from natural infection).

Infants with a moderate to severe illness should be vaccinated after recovery. In addition to the factors mentioned above, this avoids superimposing potential adverse events related to vaccination on any concurrent illness.

Minor infections, without fever or systemic upset, are not reasons to postpone vaccination.

Fever secondary to environmental factors is not a reason to postpone vaccination.

Viral shedding in stools, particularly after the first dose, could pose a risk of transmission of virus to immunocompromised close contacts. Good hygiene practices and contact precautions MUST be observed at ALL times (i.e. washing hands regularly, especially after changing nappies).

### Precautions

Co-administration studies have demonstrated that rotavirus vaccine can be given concomitantly with any of the following vaccines: Diphtheria tetanus acellular pertussis vaccine (DTPa), *Haemophilus influenzae* type b vaccine (Hib), inactivated polio vaccine (IPV), hepatitis B vaccine (HBV), hexavalent vaccines DTPa-HBV-IPV/Hib, pneumococcal conjugate vaccine and meningococcal serogroup C conjugate vaccine. The studies demonstrated that the immune responses and the safety profiles of the administered vaccines were unaffected.¹

### Drug interactions

Diarrhoea and vomiting.

¹  Adverse Reactions

#### Rotavirus vaccine

**Newborn Use Only**

**2018**

NMF Consensus Group

This is a printed copy. Refer to Neomed electronic system for the most up to date version
<table>
<thead>
<tr>
<th>Compatibility</th>
<th>Other vaccines can be given concomitantly.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incompatibility</td>
<td>No information.</td>
</tr>
<tr>
<td>Storage</td>
<td>Store between 2 and 8°C. Do NOT freeze as this reduces potency. Storage above or below the recommended temperature may decrease potency.</td>
</tr>
<tr>
<td>Special Comments</td>
<td>RotaTeq and interchangeability of vaccine: As of July 2017, RotaTeq (pentavalent human-bovine reassortant rotavirus vaccine) is not used in Australia, but it is available globally. RotaTeq is given as a 3-dose course. Upper age limit for RotaTeq is prior to 33 weeks of age. An infant might have received 1 or 2 doses of RotaTeq overseas prior to arrival in Australia. Where possible the completion of the course of rotavirus vaccine should be with the same vaccine from the same manufacturer. If either dose 1 or dose 2 of the rotavirus vaccine is given as RotaTeq (pentavalent human-bovine reassortant rotavirus vaccine) a third dose of either rotavirus vaccine should be given, provided the upper age limit and inter-vaccine interval are observed.</td>
</tr>
<tr>
<td>Evidence summary</td>
<td>Refer to full version.</td>
</tr>
<tr>
<td>References</td>
<td>Refer to full version.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Original version Date: 05/12/2015</th>
<th>Author: NMF Consensus Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current Version number: 2.1</td>
<td>Current Version Date: 19/04/2018</td>
</tr>
<tr>
<td>Risk Rating: Medium</td>
<td>Due for Review: 19/04/2021</td>
</tr>
</tbody>
</table>

**Authors Contribution**

<table>
<thead>
<tr>
<th>Original author/s</th>
<th>Ahmed Khan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revision author/s</td>
<td>Ahmed Khan, Srinivas Bolisetty</td>
</tr>
<tr>
<td>Expert review</td>
<td>Brendan McMullan, Kristine Macartney (Director, National Centre for Immunisation Research &amp; Surveillance), Jim Buttery (Paediatric Infectious Diseases Physician and Vaccinologist, Murdoch Children’s Research Institute)</td>
</tr>
<tr>
<td>Evidence Review</td>
<td>David Osborn</td>
</tr>
<tr>
<td>Nursing Review</td>
<td>Eszter Jozsa</td>
</tr>
<tr>
<td>Pharmacy Review</td>
<td>Mariella De Rosa</td>
</tr>
<tr>
<td>Final content and editing review of the original</td>
<td>Ian Whyte</td>
</tr>
<tr>
<td>Electronic version</td>
<td>Mariella De Rosa, Cindy Chen, Ian Callander</td>
</tr>
<tr>
<td>Facilitator</td>
<td>Srinivas Bolisetty</td>
</tr>
</tbody>
</table>